hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06385158 id: GenSci074-101 briefTitle: A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population overallStatus: RECRUITING date: 2024-04 date: 2024-07 date: 2024-08 date: 2024-04-25 date: 2024-04-25 name: Changchun GeneScience Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral dose escalation of GS1-144 tablets and the effects of food on the pharmacokinetics of GS1-144 in a Chinese population conditions: Vasomotor System; Labile conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 110 type: ESTIMATED name: GS1-144 tablet measure: Part 1:Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) measure: Part 2: Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). measure: Part 3: Number of Participants With TEAEs and SAEs measure: Part1,Part2 and Part3 AUC0-t- Area Under the Drug Concentration-time Curve From Time 0 to the Last Sample Collection Time t for GS1-144 measure: Part 1 , Part2 and Part 3: AUC0-infinity- Area Under the Drug Concentration-time Curve From 0 to Infinity for GS1-144 measure: Part 1, Part2 and Part 3: Cmax- Maximum Observed Plasma Concentration for GS1-144 measure: Part 1 Part2 and Part 3: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for GS1-144 measure: Part 1 Part2 and Part 3:: T1/2- Terminal Half-life for GS1-144 measure: Part 1 Part2 and Part 3: CL/F- Apparent Clearance for GS1-144 measure: Part 1 Part2 and Part 3: Vd/F- Apparent Volume of Distribution for GS1-144 measure: Cmax,ss- Observed Maximum Concentration at Steady State for GS1-144 measure: Part 3: Cmin,ss- Observed Minimum Concentration at Steady State for GS1-144 measure: Part 3: Tmax,ss- Time of Cmax at Steady State for GS1-144 measure: Part 3: Cavg,ss- Average Concentration at Steady State for GS1-144 measure: Part 3: AUC0-τ- Area Under the Drug Concentration-time Curve During the Dosing Interval at Steady State for GS1-144 measure: Part 3: CLss/F- CL for Bioavailability at Steady State for GS1-144 measure: Part 3: T1/2,ss- Terminal Half-life at Steady State for GS1-144 measure: Part 3: Accumulation Ratio for GS1-144 measure: Part 1: Baseline and placebo-adjusted changes in ∆∆QTc and other ECG parameters after oral administration of GF1-144 in healthy subjects sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huashan Hospital, Fudan University status: RECRUITING city: Shanghai state: Shanghai zip: 200040 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06385145 id: GenSci004-107 briefTitle: A Bioavailability Study of Two Different PEG-rhGH Preparations. overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2024-07-13 date: 2024-12-26 date: 2024-04-25 date: 2024-04-25 name: Changchun GeneScience Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations. conditions: Pediatric Growth Hormone Deficiency (PGHD) studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 16 type: ESTIMATED name: PEG-rhGH with new preparation (T) name: PEG-rhGH with present preparation (R) measure: Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparation measure: Pharmacokinetics (Area under the concentration-time curve from time zero to time infinity (AUC0-inf)) of PEG-rhGH with present and new preparation measure: Pharmacokinetics (Area under the concentration-time curve from time zero to the time of the last quantifiable (AUC0-last)) of PEG-rhGH with present and new preparation measure: Safety and tolerability (Number of participants with treatment-related adverse events) measure: Peak Plasma Concentration (Cmax) of Insulin-like growth factor-1 (IGF-1) with present and new preparation measure: Area under the concentration-time curve from time zero to time infinity (AUC0-inf) of Insulin-like growth factor-1 (IGF-1) with present and new preparation measure: Anti-drug antibody (Number of Participants with positive ADA) sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Chengdu Xinhua Hospital city: Chengdu state: Sichuan zip: 610000 country: China name: Xiaolan Yong, Doctor role: CONTACT phone: +862860212136 email: yongxlan@126.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06385132 id: 6447 briefTitle: Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer acronym: APPOINT overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-30 date: 2025-10-31 date: 2024-04-25 date: 2024-04-25 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Approximately 30% of cancer patients may experience psychopathological disorders. The most common psychopathological disorders in cancer patients are mood disorders, anxiety, depression, adjustment disorders, and suicidal ideation. Among depressive disorders, mixed depression, with the simultaneous presence of symptoms of both depressive and manic polarity, is associated to higher levels of chronicity, functional impairment and suicidality. These disorders can also be worsened by loneliness and demoralization.
The results obtained will be utilized for planning precocious psychological or psychiatric take-in-charge aimed at promoting psychological well-being of H\&N-C and GBM patients. conditions: Glioblastoma conditions: Head and Neck Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 207 type: ESTIMATED name: Psychological Tests' administration measure: Distress Thermometer measure: Brief Psychiatric Rating Scale sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS city: Roma zip: 00168 country: Italy name: LOREDANA DINAPOLI role: CONTACT phone: +390630154428 email: loredana.dinapoli@policlinicogemelli.it name: Loredana Dinapoli role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06385119 id: F8394-101 briefTitle: A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers. overallStatus: NOT_YET_RECRUITING date: 2024-04-24 date: 2024-10-31 date: 2024-11-25 date: 2024-04-25 date: 2024-04-25 name: Fore Biotherapeutics class: INDUSTRY briefSummary: The primary goal of this phase 1 study is to evaluate the effect of food and cobicistat on the pharmacokinetics of plixerafenib in healthy volunteers. Healthy male and female participants between the ages of 18 and 55 will be enrolled into this study. This study is looking to examine:
* The safety of plixorafenib administered alone and with cobicistat in a single dose regimen in healthy participants. conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ESTIMATED name: Plixorafenib name: Cobicistat measure: Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t). measure: AUC from time 0 extrapolated to infinity (AUC0-inf). measure: Maximum observed plasma concentration (Cmax). measure: Time to maximum observed plasma concentration (Tmax). measure: Terminal elimination rate constant (Kel). measure: Terminal phase half-life (t1/2). measure: Apparent oral clearance (CL/F). measure: Apparent volume of distribution (Vd/F). measure: Terminal rate constant calculated from the terminal slope of the log-linear regression of concentration with time (z). measure: Cumulative amount of plixorafenib excreted in urine, calculated as the sum of the product of urine concentration and urine volume (Ae). measure: Percent of dose excreted in urine in 48 hours calculated as 100*Ae/Dose. sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: PPD - Austin Research Unit city: Austin state: Texas zip: 78744 country: United States name: Kristie Miller, MD role: CONTACT phone: 877-362-2608 lat: 30.26715 lon: -97.74306 hasResults: False
nctId: NCT06385106 id: rTMS in AD briefTitle: Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-01 date: 2024-04-25 date: 2024-04-25 name: First Affiliated Hospital of Zhejiang University class: OTHER briefSummary: Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in Alzheimer's disease (AD), but studies on the improvement of sleep disorders in AD are limited. The aim of this study was to evaluate the effects of rTMS on sleep and cognition in patients with mild-to-moderate Alzheimer's disease (AD). conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Real repetitive transcranial magnetic stimulation name: Sham repetitive transcranial magnetic stimulation measure: Cognitive funtion measure: Sleep parameters measure: glymphatic system sex: ALL minimumAge: 55 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385080 id: 61186372HNC2002 briefTitle: A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer acronym: OrigAMI-4 overallStatus: RECRUITING date: 2024-04-22 date: 2026-07-17 date: 2026-07-17 date: 2024-04-25 date: 2024-04-25 name: Janssen Research & Development, LLC class: INDUSTRY briefSummary: The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, and amivantamab in addition to paclitaxel in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel. conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 117 type: ESTIMATED name: Amivantamab name: Pembrolizumab name: Paclitaxel measure: Cohorts 1, 2, and 3B: Objective Response Rate measure: Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT) measure: Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity measure: Cohorts 1, 2, and 3B: Duration of Response (DoR) measure: Cohorts 1, 2, and 3B: Clinical Benefit Rate (CBR) measure: Cohorts 1, 2, and 3B: Progression-free Survival (PFS) measure: Cohorts 1, 2, and 3B: Overall Survival (OS) measure: Cohorts 1, 2, and 3B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity measure: Cohort 1: Maximum Observed Serum Concentration (Cmax) of Amivantamab measure: Cohort 1: Time to Maximum Observed Serum Concentration (Tmax) of Amivantamab measure: Cohort 1: Area Under the Serum Concentration Curve Verses Time Curve From Time t1 to t2 (AUC[t1-t2]) of Amivantamab measure: Cohort 1: Area Under the Curve From Time Zero to tau (AUC[0-tau]) of Amivantamab measure: Cohort 1: Trough Serum Concentration (Ctrough) of Amivantamab measure: Cohort 1: Accumulation Ratio (R) of Amivantamab sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic status: RECRUITING city: Cleveland state: Ohio zip: 44195 country: United States lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06385067 id: JW-PM-DCB-2024 briefTitle: Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2025-12-30 date: 2026-12-30 date: 2024-04-25 date: 2024-04-25 name: JW Medical Systems Ltd class: INDUSTRY briefSummary: The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world.
The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm. conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: Biolimus Coated Coronary Artery Balloon Dilation Catheter measure: Target lesion failure rate (TLF) measure: Interventional success rate measure: Device-related cardiovascular clinical composite endpoint measure: Patient-related cardiovascular clinical composite endpoint measure: Major adverse cardiac events (MACEs) measure: Incidence of thrombotic events as defined by ARC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385054 id: L-027 id: 2023-A02612-43 type: REGISTRY domain: ID-RCB id: PEC23063 type: OTHER domain: Biofortis briefTitle: Effect of Probiotics on Infantile Colic Symptoms acronym: EPIC overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-02 date: 2027-02 date: 2024-04-25 date: 2024-04-29 name: Lallemand Health Solutions class: INDUSTRY name: BioFortis briefSummary: The aim of this clinical trial is to assess the impact of a probiotic formulation on participants with infantile colic. It is hypothesized that participants given the probiotic formula will have a significant reduction in their crying duration compared to participants receiving the placebo, after 4 weeks of intervention. conditions: Infantile Colic studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 70 type: ESTIMATED name: Probiotic name: Placebo measure: Change in daily crying duration measure: Change in crying patterns measure: Change in sleep duration measure: Change in maternal quality of life measure: Change in bowel habits measure: Change in gut microbiota composition measure: Probiotic strain recovery measure: Safety and tolerability of the intervention measure: Change in fecal immune markers and proteins sex: ALL maximumAge: 8 Weeks stdAges: CHILD facility: Centre Hospitalier de Boulogne-sur-Mer city: Boulogne-sur-Mer zip: 62200 country: France name: Mohamad Hage, MD role: PRINCIPAL_INVESTIGATOR lat: 50.71667 lon: 1.61667 facility: Cabinet privé Dr Regimbart-Trubuil Christine city: Bécon-les-Granits zip: 49370 country: France name: Christine Regimbart-Trubuil, MD role: PRINCIPAL_INVESTIGATOR lat: 47.50134 lon: -0.8 facility: CHU Caen Normandie city: Caen zip: 14033 country: France name: Edouard Lacotte, MD role: PRINCIPAL_INVESTIGATOR lat: 49.18585 lon: -0.35912 facility: CHU Grenoble Alpes city: La Tronche zip: 38700 country: France name: Ellen Katranji, MD role: PRINCIPAL_INVESTIGATOR lat: 45.20429 lon: 5.73645 facility: Hôpital Saint Vincent de Paul city: Lille zip: 59000 country: France name: Pr. Nicholas Kalach, MD role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Centre Hospitalier de Montauban city: Montauban zip: 82000 country: France name: Sabine Charpentier, MD role: PRINCIPAL_INVESTIGATOR lat: 44.01667 lon: 1.35 facility: CHU de NANTES city: Nantes zip: 44000 country: France name: Hugues Piloquet, MD role: PRINCIPAL_INVESTIGATOR lat: 47.21725 lon: -1.55336 facility: Biofortis, Unité d'investigation Clinique city: Paris zip: 75012 country: France name: Stéphanie Cavigoli, MD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Biofortis, Unité d'investigation Clinique city: Saint-Herblain zip: 44800 country: France name: Isabelle Metreau, MD role: PRINCIPAL_INVESTIGATOR lat: 47.21765 lon: -1.64841 facility: Centre Hospitalier du val d'Ariège city: Saint-Jean-de-Verges zip: 09000 country: France name: Lucas Percheron, MD role: PRINCIPAL_INVESTIGATOR lat: 43.01371 lon: 1.61076 hasResults: False
nctId: NCT06385041 id: BE-2-83 briefTitle: Cardiac Rehabilitation and Frailty Physical Training Program in Elderly Patients After Open Heart Surgery overallStatus: RECRUITING date: 2021-05-12 date: 2025-09-01 date: 2025-09-01 date: 2024-04-25 date: 2024-04-25 name: Vitalija Stonkuvienė class: OTHER briefSummary: The aim of the research - to evaluate the impact of interactive physical therapy tools for functional capacity, fear of falls, motivation and quality of life after open heart surgery due to ischemic heart disease and frailty in the second stage of rehabilitation. conditions: Frailty Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: Intervention group 1 name: Intervention group 2 measure: Collecting data from the medical history measure: Frailty level by Edmonton frail scale score measure: Fear of Falling by Falls Efficacy Scale International; FES-I). measure: Quality of life by EuroQoL FiveDimensionsEQ-5D-5L. measure: Motivation by Multidimensional Health Locus of Control scale measure: Change from baseline functional capacity by six minutes walking test (6MWT) measure: Change from baseline physical performance by Short Physical Performance Battery (SPPB) measure: Change from baseline muscular strength by one repetition maximum test (1RM) measure: Change from baseline grip strength by hydraulic hand dinanometer measure: Change from baseline balance parameters by Biodex Balance System SD measure: Change from baseline stance and gait parameters by Zebris Medical GmbH measure: Change from baseline cardiopulmonary exercise capacity by maximal load (maxWatt) measure: Change from baseline cardiopulmonary exercise capacity by maximal oxygen consumption (peakVO2) sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: LUHS hospital Kaunas Clinics Rehabilitation hospital of Kulautuva status: RECRUITING city: Kaunas country: Lithuania name: Vitalija Stonkuvienė role: CONTACT lat: 54.90272 lon: 23.90961 hasResults: False
nctId: NCT06385028 id: 20230213_PIANISSIMO briefTitle: Physical Activity Promotion in Osteoarthritis Patients acronym: PIANISSIMO overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2026-03-31 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: Luxembourg Institute of Health class: OTHER_GOV name: Œuvre Nationale de Secours Grande Duchesse Charlotte briefSummary: The main purpose of this project is to promote physical activity in patients with osteoarthritis. More specifically, this study aims to test the acceptability of an app to promote physical activity in the target population, and consequently the feasibility of such an approach.
The intervention is delivered via the app, which will send daily notifications on physical activity and sedentary behavior, and ask the participants to set their weekly goal (i.e., daily steps). The app will also collect daily steps count and ask the participant to fill in questionnaire on pain once a week. conditions: Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: pilot feasibility study primaryPurpose: PREVENTION masking: NONE count: 150 type: ESTIMATED name: Physical activity promotion measure: Weekly number of connections to the application over time measure: Response rate to the weekly questionnaires over time measure: Evolution of physical activity metrics measure: influence of pain on physical activity practice measure: influence of physical activity on pain report measure: long-term evolution of daily steps sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Luxembourg Institute of Health city: Strassen zip: 1445 country: Luxembourg lat: 49.62056 lon: 6.07333 hasResults: False
nctId: NCT06385015 id: IRB#23-001257 briefTitle: T-UP: Engaging Vulnerable Students in Diabetes Prevention overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-04 date: 2024-05 date: 2025-06 date: 2024-04-25 date: 2024-04-26 name: University of California, Los Angeles class: OTHER name: American Diabetes Association briefSummary: The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity.
The specific aims are to: 1) Evaluate the efficacy of adolescents and young adults (AYA)-tailored version of the University of California Diabetes Prevention Program (UC DPP) for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months); and, 2) Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP.
The investigators will randomize participants to the AYA-tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the AYA-tailored DPP in the following academic year. Participants will be organized into groups within their DPP cohort based on their student status and/or place of residence. The intervention will include 19 sessions (18 in-person and 1 on-demand) covering 24 DPP modules; each session is approximately an hour in length and will be moderated by a lifestyle coach. At the end of each session, intervention participants will receive an email/text with a unique link to a brief REDCap survey to ascertain acceptability of the session. Control group will receive access to materials about study habits, alcohol use, and financial literacy. Control group will receive materials via e-mail for participants to review on their own time and will receive acceptability surveys. A research assistant (RA) will meet with control participants via Zoom to explain the materials. Participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire via REDCap and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey. conditions: Diabetes Mellitus, Type 2 conditions: PreDiabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: NONE count: 80 type: ACTUAL name: Tailored DPP Intervention measure: Change in weight (pounds, lbs) between baseline and 9-month follow-up measure: Change in self-reported quality of life (Centers for Disease Control and Prevention Health-Related Quality of Life-14 item (CDC HRQOL-14)) between baseline and 9-month follow-up sex: ALL minimumAge: 17 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: University of California, Los Angeles city: Los Angeles state: California zip: 90095 country: United States lat: 34.05223 lon: -118.24368 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-09-22 uploadDate: 2024-01-23T16:50 filename: ICF_000.pdf size: 203319 hasResults: False